

ASX Announcement

18 November 2016

Approval of extension of time to hold 2016 Annual General Meeting

Melbourne, Australia; 17 November 2016: Mach7 Technologies Limited (**Mach7** or the **Company**) (ASX:**M7T**) confirms that it has received approval from the Australian Securities and Investments Commission (**ASIC**) of the Company's application for an extension of time to hold its 2016 Annual General Meeting (**Application**).

At the time of the Application, Mach7 was in the process of finalising its capital raising negotiations, and determined to seek an extension to enable it to seek, if required, capital raising related shareholder approvals at the AGM.

In response to the Application, ASIC has extended the period within which Mach7 must hold its 2016 AGM from 30 November 2016 to 7 December 2016.

The Company confirms that its 2016 AGM will be held in accordance with the Notice of Meeting and Explanatory Memorandum which was made available to shareholders on 7 November 2016. The details of Mach7's 2016 AGM are as follows:

Date: Wednesday, 7 December 2016

Time:4.00 pm (Melbourne time)

Venue: RSM Australia Partners, Level 21, 55 Collins Street Melbourne, Victoria, 3000

- ENDS

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced <u>clinical viewing</u> and optimised <u>vendor neutral archiving</u> solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit <u>www.mach7t.com</u>

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit <u>www.3dmedical.com.au</u>



ASX Announcement

18 November 2016

Contacts:

Albert Liong CEO +1 650 743 0167 (U.S.) albert.liong@mach7t.com Jenni Pilcher CEO Australia, CFO +61 3 9646 2222 (Australia) jenni.pilcher@mach7t.com Julia Vaughn Investor Relations (U.S.) +1 802 768 0143 (U.S.) julia.vaughn@mach7t.com